Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle (Q37173162)

18 August 2017

Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle (English)

1 reference

18 August 2017

0 references

14

Mark E Davis

1 reference

18 August 2017

12

Devin T Wiley

1 reference

18 August 2017

1

Scott Eliasof

1 reference

18 August 2017

Douglas Lazarus

2

1 reference

18 August 2017

Christian G Peters

3

1 reference

18 August 2017

Roy I Case

4

1 reference

18 August 2017

Roderic O Cole

5

1 reference

18 August 2017

Jungyeon Hwang

6

1 reference

18 August 2017

Thomas Schluep

7

1 reference

18 August 2017

Joseph Chao

8

1 reference

18 August 2017

James Lin

9

1 reference

18 August 2017

Yun Yen

10

1 reference

18 August 2017

Han Han

11

1 reference

18 August 2017

Jonathan E Zuckerman

13

1 reference

18 August 2017

language of work or name

English

0 references

publication date

26 August 2013

1 reference

18 August 2017

6

1 reference

Proceedings of the National Academy of Sciences of the United States of America

inferred from page(s)

published in

1 reference

18 August 2017

110

1 reference

18 August 2017

37

1 reference

18 August 2017

15127-15132

1 reference

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773776

Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773776

Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773776

Interpatient pharmacokinetic and pharmacodynamic variability of carrier-mediated anticancer agents

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773776

Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773776

Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773776

Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773776

The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773776

Polymeric micelles in anticancer therapy: targeting, imaging and triggered release

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773776

Strategies in the design of nanoparticles for therapeutic applications

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773776

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773776

Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773776

Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773776

Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773776

Nanoparticle therapeutics: an emerging treatment modality for cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773776

Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773776

Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773776

A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773776

A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773776

Synthesis of linear, beta-cyclodextrin-based polymers and their camptothecin conjugates

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773776

Nanotechnology: Carrying drugs

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773776

Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773776

Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773776

Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773776

An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773776

Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773776

Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773776

Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773776

Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773776

A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773776

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3773776

[Interaction of camptothecin derivatives with human plasma proteins in vitro]

3 September 2018

1 reference

12 December 2020

The structural basis of camptothecin interactions with human serum albumin: impact on drug stability

1 reference

12 December 2020

Marked interspecies variations concerning the interactions of camptothecin with serum albumins: a frequency-domain fluorescence spectroscopic study

1 reference

12 December 2020

Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker

1 reference

12 December 2020

Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol-PM) in patients with solid tumors

1 reference

12 December 2020

Proof of concept for next-generation nanoparticle drugs in humans

1 reference

12 December 2020

Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies

1 reference

12 December 2020

Companies in footrace to deliver RNAi

1 reference

12 December 2020

Identifiers

DOI

10.1073/PNAS.1309566110

1 reference

18 August 2017

0 references

1 reference

18 August 2017

PubMed publication ID

23980155

1 reference